| |
Learn de-risking strategies in our whitepaper and explore the future of precision treatments from our survey of 100+ oncology professionals. 
|
|
Today’s Big NewsOct 18, 2024 |
|
Gene and cellular therapies hold the extraordinary potential to transform
global health care. Download the QPS White Paper to explore the 5 critical
criteria to consider when choosing the best CRO for your next cell and gene
therapy development program. ..png)
|
|
| By Gabrielle Masson The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. |
|
|
|
By Angus Liu After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. |
By Fraiser Kansteiner A dozen consumer groups and trade unions penned a letter to Lina Khan, chair of the U.S. Federal Trade Commission, urging the antitrust agency to block Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent. The call to action comes a week after Sen. Elizabeth Warren voiced similar concerns. |
By Darren Incorvaia,Zoey Becker It’s been a whirlwind year for Joerg Moeller, M.D. After being appointed CEO of BenevolentAI in January, Moeller is now out the door of the AI drug discoverer, effective immediately. |
|
Wednesday, October 23, 2024 | 11am ET / 8am PT Large, deeply characterized patient cohorts are one of the most promising data resources today for understanding disease biology and developing new medicines. Join us as we explore how this data is driving the next generation of pharmaceutical development. Learn how to leverage genetic research in today's highly competitive landscape. Register now. 
|
|
By Andrea Park The Big Pharma partnered with the Obesity Action Coalition to produce a set of images deemed to be more accurate and respectful in their portrayals of people with obesity than other images often used to represent the condition in the media and healthcare settings. |
By Kevin Dunleavy Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody candidate clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season. |
By Zoey Becker Novo Nordisk received good news from European drug reviewers on its hemophilia treatment, while PTC Therapeutics' Duchenne Muscular Dystrophy therapy was again recommended for rejection upon a re-examination. |
By Darren Incorvaia London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative Medicine at Boston University and Boston Medical Center to develop new models for lung diseases like pulmonary fibrosis. |
By Fraiser Kansteiner Baxter has said the first IV product shipments cleared by the FDA for temporary importation are set to arrive in the U.S. this weekend. By the end of the year, the company expects nearly 18,000 tons of product from Europe and Asia to reach The States. The plan comes after Baxter's North Carolina production facility suffered flooding from Hurricane Helene late last month. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” we catch up with three past Fierce 15 honorees to gain their insights, experiences and visions for the evolving biotech landscape. |
|
|---|
|
|
|
Thursday, October 24, 2024 | 1pm ET / 10am PT We will explore how incorporating comprehensive genetic services, like genetic testing access programs and clinical trial matching services, can increase identification of patients who meet program-specific inclusion/exclusion criteria, helping more patients benefit from life-changing therapeutics. Register today! 
|
|
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
